Gene therapy for arthritis

P. D. Robbins, Christopher H Evans, Y. Chernajovsky

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Rheumatoid arthritis is an autoimmune disease with intraarticular inflammation and synovial hyperplasia that results in progressive degradation of cartilage and bone, in severe cases it causes systemic complications. Recently, biological agents that suppress the activities of proinflammatory cytokines have shown efficacy as antiarthritic drugs, but require frequent administration. Thus, gene transfer approaches are being developed as an alternative approach for targeted, more efficient and sustained delivery of inhibitors of inflammatory cytokines as well as other therapeutic agents. Indeed, the efficacy of gene transfer for the treatment of arthritis has been demonstrated in mouse, rat, rabbit, and horse models of disease whereas the feasibility of the approach has been demonstrated in Phase I clinical trials. In this review, the current status of both preclinical and clinical arthritis gene therapy is presented. In addition, the advantages and disadvantages of different types of vectors, target cells and therapeutic genes being developed for the treatment of arthritis are summarized. Finally, the future directions of the rapidly developed field of arthritis gene therapy are outlined.

Original languageEnglish (US)
Pages (from-to)902-911
Number of pages10
JournalGene Therapy
Volume10
Issue number10
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Genetic Therapy
Arthritis
Horse Diseases
Cytokines
Genes
Clinical Trials, Phase I
Biological Factors
Therapeutics
Autoimmune Diseases
Cartilage
Hyperplasia
Rheumatoid Arthritis
Rabbits
Inflammation
Bone and Bones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Genetics

Cite this

Robbins, P. D., Evans, C. H., & Chernajovsky, Y. (2003). Gene therapy for arthritis. Gene Therapy, 10(10), 902-911. https://doi.org/10.1038/sj.gt.3302040

Gene therapy for arthritis. / Robbins, P. D.; Evans, Christopher H; Chernajovsky, Y.

In: Gene Therapy, Vol. 10, No. 10, 05.2003, p. 902-911.

Research output: Contribution to journalArticle

Robbins, PD, Evans, CH & Chernajovsky, Y 2003, 'Gene therapy for arthritis', Gene Therapy, vol. 10, no. 10, pp. 902-911. https://doi.org/10.1038/sj.gt.3302040
Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Therapy. 2003 May;10(10):902-911. https://doi.org/10.1038/sj.gt.3302040
Robbins, P. D. ; Evans, Christopher H ; Chernajovsky, Y. / Gene therapy for arthritis. In: Gene Therapy. 2003 ; Vol. 10, No. 10. pp. 902-911.
@article{2cfae59c66e24cfeb5ae286f7f341561,
title = "Gene therapy for arthritis",
abstract = "Rheumatoid arthritis is an autoimmune disease with intraarticular inflammation and synovial hyperplasia that results in progressive degradation of cartilage and bone, in severe cases it causes systemic complications. Recently, biological agents that suppress the activities of proinflammatory cytokines have shown efficacy as antiarthritic drugs, but require frequent administration. Thus, gene transfer approaches are being developed as an alternative approach for targeted, more efficient and sustained delivery of inhibitors of inflammatory cytokines as well as other therapeutic agents. Indeed, the efficacy of gene transfer for the treatment of arthritis has been demonstrated in mouse, rat, rabbit, and horse models of disease whereas the feasibility of the approach has been demonstrated in Phase I clinical trials. In this review, the current status of both preclinical and clinical arthritis gene therapy is presented. In addition, the advantages and disadvantages of different types of vectors, target cells and therapeutic genes being developed for the treatment of arthritis are summarized. Finally, the future directions of the rapidly developed field of arthritis gene therapy are outlined.",
author = "Robbins, {P. D.} and Evans, {Christopher H} and Y. Chernajovsky",
year = "2003",
month = "5",
doi = "10.1038/sj.gt.3302040",
language = "English (US)",
volume = "10",
pages = "902--911",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Gene therapy for arthritis

AU - Robbins, P. D.

AU - Evans, Christopher H

AU - Chernajovsky, Y.

PY - 2003/5

Y1 - 2003/5

N2 - Rheumatoid arthritis is an autoimmune disease with intraarticular inflammation and synovial hyperplasia that results in progressive degradation of cartilage and bone, in severe cases it causes systemic complications. Recently, biological agents that suppress the activities of proinflammatory cytokines have shown efficacy as antiarthritic drugs, but require frequent administration. Thus, gene transfer approaches are being developed as an alternative approach for targeted, more efficient and sustained delivery of inhibitors of inflammatory cytokines as well as other therapeutic agents. Indeed, the efficacy of gene transfer for the treatment of arthritis has been demonstrated in mouse, rat, rabbit, and horse models of disease whereas the feasibility of the approach has been demonstrated in Phase I clinical trials. In this review, the current status of both preclinical and clinical arthritis gene therapy is presented. In addition, the advantages and disadvantages of different types of vectors, target cells and therapeutic genes being developed for the treatment of arthritis are summarized. Finally, the future directions of the rapidly developed field of arthritis gene therapy are outlined.

AB - Rheumatoid arthritis is an autoimmune disease with intraarticular inflammation and synovial hyperplasia that results in progressive degradation of cartilage and bone, in severe cases it causes systemic complications. Recently, biological agents that suppress the activities of proinflammatory cytokines have shown efficacy as antiarthritic drugs, but require frequent administration. Thus, gene transfer approaches are being developed as an alternative approach for targeted, more efficient and sustained delivery of inhibitors of inflammatory cytokines as well as other therapeutic agents. Indeed, the efficacy of gene transfer for the treatment of arthritis has been demonstrated in mouse, rat, rabbit, and horse models of disease whereas the feasibility of the approach has been demonstrated in Phase I clinical trials. In this review, the current status of both preclinical and clinical arthritis gene therapy is presented. In addition, the advantages and disadvantages of different types of vectors, target cells and therapeutic genes being developed for the treatment of arthritis are summarized. Finally, the future directions of the rapidly developed field of arthritis gene therapy are outlined.

UR - http://www.scopus.com/inward/record.url?scp=0038146937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038146937&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302040

DO - 10.1038/sj.gt.3302040

M3 - Article

VL - 10

SP - 902

EP - 911

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 10

ER -